Evofosfamide

Overview

Evofosfamide (TH-302) is a hypoxia -activated proagent with IC 50 of 10 μM and 1000 μM in hypoxia (N 2 ) and normoxia (21% O 2 ), respectively.

Application

Products | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-10535
• CAS No.: 918633-87-1
• Molecular Formula: C9H16Br2N5O4P
• Molecular Weight: 449.04
• Purity: 98.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution
• Availability: In-stock

Source

Original product source